Log in to your Inderes Free account to see all free content on this page.
NextCell Pharma
1.5 SEK -0.66%2 investors are following this company
NextCell Pharma operates in the healthcare sector. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NXTCL
Daily low / high price
1.42 / 1.55
SEK
Market cap
109.64M SEK
Turnover
146.4K SEK
Volume
98K
Financial calendar
Annual report
24.10.2024
General meeting
28.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Diamyd Medical AB | 12.5 % | 12.5 % |
Avanza Pension | 10.9 % | 10.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
NextCell Pharma AB: NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue
NextCell Pharma AB: NextCell's rights issue oversubscribed
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio